Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-CHIC Study
2015-002846-30Phase 2Completed
- Sponsor
- Helsinki University Hospital
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, prednisone, vincristine, methotrexate, cyclophosphamide and 3 more in diffuse large B-cell lymphoma (DLBCL), sponsored by Helsinki University Hospital. Primary endpoint: Time to treatment failure. Started Jul 2016; status: completed.
02
Drugs
rituximabprednisonevincristinemethotrexatecyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2015-002846-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002846-30.